KCP
IMMX icon

Kera Capital Partners’s Immix Biopharma IMMX Stock Holding History

Kera Capital Partners’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Hold
13,000
– – 0.01% 622
2026
Q1 		$118K Hold
13,000
– – 0.01% 559
2025
Q4 		$75.8K Buy
+13,000
New +$53.5K 0.01% 545

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kera Capital Partners's IMMX Position: Q2 2026 in Review

Kera Capital Partners held its Immix Biopharma (IMMX) position steady in Q2 2026 at 13,000 shares worth $134K. The position accounts for 0.01% of the portfolio, ranked #622.

Kera Capital Partners first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Kera Capital Partners held 13,000 shares of Immix Biopharma worth $134K as of Q2 2026.
  • Kera Capital Partners left its Immix Biopharma share count unchanged in Q2 2026.
  • Immix Biopharma made up 0.01% of Kera Capital Partners's portfolio in Q2 2026, its #622 holding.
  • Kera Capital Partners first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.